These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 12869459)

  • 21. Spironolactone in patients with heart failure.
    Vanpee D; Swine C
    N Engl J Med; 2000 Jan; 342(2):133; author reply 133-4. PubMed ID: 10636753
    [No Abstract]   [Full Text] [Related]  

  • 22. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone.
    Berry C; McMurray J
    Am J Med; 2001 Nov; 111(7):587. PubMed ID: 11705445
    [No Abstract]   [Full Text] [Related]  

  • 23. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.
    Schepkens H; Vanholder R; Billiouw JM; Lameire N
    Am J Med; 2001 Apr; 110(6):438-41. PubMed ID: 11331054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Spironolactone and potassium].
    Kjeldsen K
    Ugeskr Laeger; 2004 Nov; 166(48):4392; author reply 4392-3. PubMed ID: 15587639
    [No Abstract]   [Full Text] [Related]  

  • 25. Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
    Muzzarelli S; Maeder MT; Toggweiler S; Rickli H; Nietlispach F; Julius B; Burkard T; Pfisterer ME; Brunner-La Rocca HP;
    Am J Cardiol; 2012 Mar; 109(5):693-8. PubMed ID: 22152974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure.
    Secora AM; Shin JI; Qiao Y; Alexander GC; Chang AR; Inker LA; Coresh J; Grams ME
    Mayo Clin Proc; 2020 Nov; 95(11):2408-2419. PubMed ID: 33153631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
    Pitt B; Zannad F; Remme WJ; Cody R; Castaigne A; Perez A; Palensky J; Wittes J
    N Engl J Med; 1999 Sep; 341(10):709-17. PubMed ID: 10471456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serious adverse events experienced by patients with chronic heart failure taking spironolactone.
    Berry C; McMurray JJ
    Heart; 2001 Apr; 85(4):E8. PubMed ID: 11250985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The safety of spironolactone treatment in patients with heart failure.
    Anton C; Cox AR; Watson RD; Ferner RE
    J Clin Pharm Ther; 2003 Aug; 28(4):285-7. PubMed ID: 12911680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. More on the "Triple Whammy": antihypertensive drugs, non-steroidal anti-inflammatory agents and acute kidney injury - a case/non-case study in the French pharmacovigilance database.
    Fournier JP; Sommet A; Durrieu G; Poutrain JC; Lapeyre-Mestre M; Montastruc JL;
    Ren Fail; 2014 Aug; 36(7):1166-8. PubMed ID: 24826803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension.
    Ritter JM
    BMJ; 2011 Apr; 342():d1673. PubMed ID: 21474511
    [No Abstract]   [Full Text] [Related]  

  • 33. Diabetes may be independent risk factor for hyperkalaemia.
    Jarman PR; Mather HM
    BMJ; 2003 Oct; 327(7418):812. PubMed ID: 14525902
    [No Abstract]   [Full Text] [Related]  

  • 34. Spironolactone use and renal toxicity: population based longitudinal analysis.
    Wei L; Struthers AD; Fahey T; Watson AD; Macdonald TM
    BMJ; 2010 May; 340():c1768. PubMed ID: 20483947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Severe hyperkalemia associated to the use of losartan and spironolactone: case report].
    Kauffmann R; Orozco R; Venegas JC
    Rev Med Chil; 2005 Aug; 133(8):947-52. PubMed ID: 16163434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism.
    Poggio R; Grancelli HO; Miriuka SG
    Postgrad Med J; 2010 Mar; 86(1013):136-42. PubMed ID: 20237007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of heart failure with spironolactone--trial and tribulations.
    McMurray JJ; O'Meara E
    N Engl J Med; 2004 Aug; 351(6):526-8. PubMed ID: 15295043
    [No Abstract]   [Full Text] [Related]  

  • 38. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study.
    Svensson M; Gustafsson F; Galatius S; Hildebrandt PR; Atar D
    BMJ; 2003 Nov; 327(7424):1141-2. PubMed ID: 14615339
    [No Abstract]   [Full Text] [Related]  

  • 39. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.
    Shah KB; Rao K; Sawyer R; Gottlieb SS
    J Am Coll Cardiol; 2005 Sep; 46(5):845-9. PubMed ID: 16139135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
    Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.